New combo therapy tested for tough cancers that resist immunotherapy
NCT ID NCT04879849
Summary
This early-stage study tested a new drug, TAK-676, combined with an existing immunotherapy (pembrolizumab) after a short course of radiation. It involved 34 adults with advanced lung cancer, triple-negative breast cancer, or head and neck cancer that had stopped responding to standard immunotherapies. The main goals were to find the safest dose of TAK-676 and check for early signs that the treatment might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Duarte, California, 91010-3012, United States
-
Laura And Isaac Perlmutter Cancer Center
New York, New York, 10016-4744, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213-2933, United States
-
University of Chicago
Chicago, Illinois, 60637-1443, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0021, United States
Conditions
Explore the condition pages connected to this study.